Treatment accepted for restricted use within NHS Scotland.
Randomised phase III study showed secukinumab significantly improved symptoms compared with placebo.
Niraparib recommended for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Aminoglycosides (gentamicin, amikacin, tobramycin, and neomycin): increased risk of deafness in patients with mitochondrial mutations
Genetic testing should not delay urgently needed aminoglycoside treatment but may be considered, especially before the start of recurrent or long-term treatment.
Regulatory Alerts, Fertility, pregnancy and childbirth, Mental health and behavioural conditions, Psychiatry
SSRI/SNRI antidepressant medicines: small increased risk of postpartum haemorrhage when used in the month before delivery
Prescribers should consider this risk in the context of an individual patient’s bleeding and thrombotic risk assessment during the peripartum period and the benefits of antidepressants for the patient’s mental health during this time.
Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis
Liver monitoring requirements and discontinuation criteria for fingolimod have been updated following reports of serious liver injury.